Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies ...Middle East

Key Highlights: Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). ivonescimab outperforms pembrolizumab in Phase III study for first-line PD-L1+ NSCLC: mPFS...

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies )

Also on site :

• Ministry of Economy Establishes the Syrian-Canadian Business Council
• Today’s NYT ‘Strands’ Hints, Spangram and Answers for Friday, July 4
• Beloved ‘60s Icon, 75, Dazzles London Event in Chic Pink Blazer and High-Top Sneakers